Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Galanin receptor ligands.

Xiaoying Lu1, Linda Lundström, Ulo Langel

  • 1Department of Neuropharmacology, The Harold L. Dorris Neurological Research Center, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.

Neuropeptides
|June 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of peripheral optical errors in age-related macular degeneration.

Journal of optometry·2026
Same author

Assessing Peripheral Focus in Myopes and Non-myopes: Introducing "Depth-of-refraction".

Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)·2026
Same author

Asymmetry between nasal and temporal refraction with accommodation in myopes and emmetropes.

Biomedical optics express·2026
Same author

Roadmap on advances in visual and physiological optics.

Journal of optics (2010)·2025
Same author

Carbon dot-based polyplexes with cell penetration peptides for gene transfection.

RSC advances·2025
Same author

Single cell phototransfection of mRNAs encoding SARS-CoV2 spike and nucleocapsid into human astrocytes results in RNA dependent translation interference.

Frontiers in drug delivery·2025
Same journal

The hemoglobin-derived peptide LVV-H7 attenuates select behavioral alterations in male spontaneously hypertensive rats.

Neuropeptides·2026
Same journal

Neuropeptide Y in cancer metastasis and chemoresistance.

Neuropeptides·2026
Same journal

Expression of the Galanin system in the human pancreas, pancreatitis, and pancreatic cancer: Association with nodal involvement and perineural invasion.

Neuropeptides·2026
Same journal

PACAP promotes mitochondrial biogenesis in rat primary chondrocytes via the SIRT1/PGC-1α pathway.

Neuropeptides·2026
Same journal

Galanin receptor 2: A multifunctional modulator in neurological diseases - Structure, mechanisms, and therapeutic prospects.

Neuropeptides·2026
Same journal

Re-thinking neuropeptide therapeutics: What Neuropeptide Y and Galanin teach us about stress, resilience, and drug design.

Neuropeptides·2026
See all related articles

Galanin receptors (GalR1-3) are key drug targets due to their widespread effects. However, developing selective agonists and antagonists remains challenging, despite ongoing research and ligand characterization.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • Galanin receptors (GalR1-3) are G protein-coupled receptors with broad distribution in the central and peripheral nervous systems.
  • Galanin and its receptors exhibit numerous physiological and pharmacological effects, making them attractive targets for therapeutic intervention.
  • Despite significant interest, developing high-affinity and subtype-selective galanin receptor agonists and antagonists has proven difficult.

Purpose of the Study:

  • To summarize the properties of known galanin receptor ligands.
  • To provide an updated pharmacological characterization of these ligands, including new data.
  • To assess the progress in developing selective ligands for GalR1-3.

Main Methods:

  • Literature review of galanin ligands published up to late 2004.

Related Experiment Videos

  • Pharmacological characterization of galanin ligands.
  • Analysis of ligand affinity and selectivity for GalR1-3 subtypes.

    • Main Results:

    • A comprehensive overview of galanin ligands available in early 2000s research.
    • New pharmacological data complementing existing characterizations.
    • Identification of limitations in current ligand selectivity and affinity.

    Conclusions:

    • Galanin receptors remain important therapeutic targets.
    • The development of selective and high-affinity ligands for galanin receptor subtypes is ongoing but challenging.
    • Further research is needed to advance the therapeutic potential of targeting galanin receptors.